Indian pharmaceutical firm Zydus Lifesciences proclaimed the release of Anyra, the nation’s first biosimilar Aflibercept 2 mg created domestically to tackle vision problems associated with conditions such as diabetic retinopathy and various retinal ailments. The action is important for enhancing local biologics skills and offering affordable, high-quality eye care options to the people of India. The nation hosts 100 million individuals affected by diabetes, and the introduction of this biosimilar may aim to address the increasing need for retinal disorder therapies in the country. The new biosimilar is anticipated to enhance the accessibility of eye care treatments for the public by offering a cost-effective alternative to current biologic medications available. The initiative is anticipated to enhance India’s standing in the global biosimilar market and bolster the nation’s research abilities in the pharmaceutical field via homegrown advancements in biosimilar drug creation. Zydus Lifesciences has confirmed a partnership with Regeneron and Bayer concerning the medication, potentially aimed at boosting global collaborations in the creation of advanced therapeutics in the nation. Zydus Lifesciences' initiative also aims to enhance the concentration of Indian pharmaceutical firms on advanced biologics and specialized solutions, potentially boosting the nation's standing in the pharmaceutical industry in the future